Controversies regarding the prophylactic management of adults with severe haemophilia A

Haemophilia

Volumn 15, Issue SUPPL. 2, 2009, Pages 5-22

  Valentino, L A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; HEALTH CARE ORGANIZATION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INDIVIDUALIZATION; JOINT RADIOGRAPHY; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; PATIENT CARE; PATIENT COMPLIANCE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANGE OF MOTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FACTOR VIII; GUIDELINES AS TOPIC; HEMOPHILIA A; HUMANS; INFANT; INTRACRANIAL HEMORRHAGES; JOINT DISEASES; MALE; RISK FACTORS; YOUNG ADULT;

EID: 73249136485     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02159.x     Document Type: Article

References (78)

1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001, 85:560.
2. Berntorp E, Astermark J, Bjorkman S. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003, 9(Suppl. 1):1-4.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
4. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965, 77(Suppl.):3-132.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994, 236:391-9.
6. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997, 241:395-400.
7. Fischer K, van der Bom JG, Molho P. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-52.
8. van den Berg HM, Fischer K, Mauser-Bunschoten EP. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001, 112:561-5.
9. van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971, 45:120-7.
10. Feldman BM, Pai M, Rivard GE. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4:1228-36.
11. Bleeding and clotting disorders surveillance. Summary report of UDC activity. http://www2a.cdc.gov/ncbddd/htcweb/index.asp, Available at: . Accessed December 7, 2009
12. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation web site. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007, Available at: . Accessed December 7, 2009 (Adopted November 4, 2007)
13. Srivastava A, Giangrande P, Poon MC, McCraw A, Wiedel J. WFH Guidelines for the management of hemophilia. http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf, Available at: . Accessed December 7, 2009
14. Berntorp E, Boulyjenkov V, Brettler D. Modern treatment of haemophilia. Bull World Health Organ 1995, 73:691-701.
15. Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008, 119:115-23.
16. Hay CRM. Prophylaxis in adults with haemophilia. Haemophilia 2007, 13(Suppl. 2):10-5.
17. Plug I, van der Bom JG, Peters M. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004, 104:3494-500.
18. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003, 9:549-54.
19. Blanchette P, Rivard G, Israels S. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia 2004, 10:679-83.
20. Tagliaferri A, Franchini M, Coppola A. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008, 14:945-51.
21. Richards M, Altisent C, Batorova A. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007, 13:473-9.
22. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009, 15:1014-21.
23. Trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult subjects compared to that of episodic treatment (SPINART). Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT00623480?term=hemophilia+and+prophylaxis+and+adults&rank=2, gov web site. Available at: . Accessed December 7, 2008
24. Gilbert MS. Musculoskeletal complications of haemophilia: the joint. Haemophilia 2000, 6(Suppl. 1):34-7.
25. The Universal Data Collection Program. http://www.cdc.gov/ncbddd/hbd/documents/UDC7(1).pdf, July 2005/Vol 7/No.1. Available at: . Accessed December 7, 2009
26. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004, 10:147-57.
27. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008, 14(Suppl. 3):196-201.
28. Kyngas H. Compliance of adolescents with chronic disease. J Clin Nurs 2000, 9:549-56.
29. Soucie JM, Nuss R, Evatt B. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000, 96:437-42.
30. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006, 12(Suppl. 3):117-21.
31. Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia 2007, 13:279-86.
32. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005, 11:240-4.
33. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006, 12:514-7.
34. Journeycake JM, Miller KL, Anderson AM, Buchanan GR, Finnegan M. Arthroscopic synovectomy in children and adolescents with hemophilia. J Pediatr Hematol Oncol 2003, 25:726-31.
35. van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 2006, 12(Suppl. 3):159-68.
36. Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg 2004, 12:234-45.
37. Rivard GE, Girard M, Belanger R, Jutras M, Guay JP, Marton D. Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am 1994, 76:482-8.
38. Siegel HJ, Luck JV, Siegel ME, Quinones C. Phosphate-32 colloid radiosynovectomy in hemophilia: outcome of 125 procedures. Clin Orthop Relat Res 2001, 392:409-17.
39. Lusher J, Abildgaard C, Arkin S. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004, 2:574-83.
40. Viel KR, Ameri A, Abshire TC. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009, 360:1618-27.
41. DiMichele D, Kroner B. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. Haematologica 2000, 85:40-2. Discussion 2-4
42. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005, 130:107-12.
43. Su Y, Wong WY, Lail A, Donfield SM, Konzal S, Gomperts E. Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS. Haemophilia 2007, 13:387-90.
44. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe hemophilia A. Haemophilia 2007, 13(Suppl. 4):1-16.
45. Conlan MG, Folsom AR, Finch A. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993, 70:380-5.
46. Rosendaal FR, Varekamp I, Smit C. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989, 71:71-6.
47. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995, 123:823-7.
48. Foley C, Nichols LA, Ragni MV. Atherosclerosis and predictors of cardiovascular mortality in hemophilia. Blood 2008, 112. Abstract 1216
49. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003, 362:351-4.
50. Baarslag MA, Rafi S, Kruip MJHA, Peters M, Kamphuisen PW. The inverse association between hemophilia and cardiovascular mortality is not explained by differences in cardiovascular risk profile. J Thromb Haemost 2009, 7. Abstract PP-WE-548
51. Zwiers M, Lijfering WM, Meijer K, Lefrandt JD, Smit AJ, van der Meer J. Hemophilia A and cardiovascular events: a case series. J Thromb Haemost 2009, 7. Abstract PP-WE-554
52. Sharathkumar A, Trawinski B, Soucie JM, Griest A, Haddix C, Shapiro A. Cardiovascular disease in patients with hemophilia: single centre experience. Blood 2008, 112. Abstract 2272
53. Konkle BA, Kessler C, Aledort L. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia http://dx.doi.org/10.1111/j.1365-2516.2009.02066.x, [published online ahead of print July 21, 2009] doi:
54. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006, 116:120-5.
55. Coppola A, Rivolta GF, Lapecorella M. Management of acute coronary syndromes in hemophiliacs: a new challenge between haemorrhagic and thrombotic risk. J Thromb Haemost 2009, 7:497. (Abstract PP-MO-525)
56. Seung KB, Park DW, Kim YH. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008, 358:1781-92.
57. Helft G, Gilard M, Le Feuvre C, Zaman AG. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 2006, 3:673-80.
58. Benzadon MN, Thierer JM, Trivi M. Is early anticoagulation necessary after biological aortic valve replacement? Int J Cardiol 2008, 128:422-3.
59. van Leth F, Phanuphak P, Stroes E. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.
60. Nelson MD, Maeder MA, Usner D. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study. Haemophilia 1999, 5:306-12.
61. Stieltjes N, Calvez T, Demiguel V. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 2005, 11:452-8.
62. Traivaree C, Blanchette V, Armstrong D, Floros G, Stain AM, Carcao MD. Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding. Haemophilia 2007, 13:552-9.
63. Luchtman-Jones L, Valentino LA, Manno C. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 2006, 12:82-6.
64. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008, 140:378-84.
65. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003, 9:573-7.
66. Mishra P, Naithani R, Dolai T. Intracranial haemorrhage in patients with congenital haemostatic defects. Haemophilia 2008, 14:952-5.
67. Tovi D, Nilsson IM, Thulin CA. Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage. Acta Neurol Scand 1973, 49:1-9.
68. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008, 14:39-43.
69. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002, 8:280-7.
70. Ewenstein BM, Valentino LA, Journeycake JM. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004, 10:629-48.
71. Valentino LA, Kapoor M. Central venous access devices in patients with hemophilia. Expert Rev Med Devices 2005, 2:699-711.
72. Decker MD, Edwards KM. Central venous catheter infections. Pediatr Clin North Am 1988, 35:579-612.
73. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004, 10:134-46.
74. Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment center experience. Haemophilia 1997, 3:194-8.
75. Girvan DP, deVeber LL, Inwood MJ, Clegg EA. Subcutaneous infusion ports in the pediatric patient with hemophilia. J Pediatr Surg 1994, 29:1220-3.
76. Vascular access for hemodialysis. http://kidney.niddk.nih.gov/kudiseases/pubs/pdf/vascularaccess.pdf, NIH Publication No. 05-4554. January 2005. Available at: . Accessed December 7, 2009
77. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003, 123:502-6.
78. McCarthy WJ, Valentino LA, Bonilla AS. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2007, 45:986-90.